top of page
The Professional Network for Healthcare Experts
Boehringer Ingelheim and Envisagenics sign oncology collaboration worth more than $1bn
Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.
nuaxia
Sep 232 min read
GSK acquires Chimagen trispecific T-cell engager programme in deal worth up to $750m
GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.
nuaxia
Sep 162 min read
bottom of page